Translational models of prostate cancer bone metastasis

被引:107
作者
Berish, Richard B. [1 ,2 ]
Ali, Aymon N. [1 ]
Telmer, Patrick G. [1 ]
Ronald, John A. [2 ,3 ]
Leong, Hon S. [1 ,2 ,4 ]
机构
[1] Univ Western Ontario, Dept Surg, Div Urol, Schulich Sch Med & Dent, London, ON, Canada
[2] Univ Western Ontario, Dept Microbiol & Immunol, Schulich Sch Med & Dent, London, ON, Canada
[3] Univ Western Ontario, Dept Med Biophys, Schulich Sch Med & Dent, London, ON, Canada
[4] Mayo Clin, Dept Urol Physiol & Biomed Engn, Coll Med, Rochester, MN USA
关键词
PATIENT-DERIVED XENOGRAFTS; CARCINOMA-CELL-LINE; EPIDERMAL GROWTH-FACTOR; IN-VIVO MODEL; TUMOR-GROWTH; MOUSE MODEL; ANDROGEN RECEPTOR; OSTEOLYTIC LESIONS; MOLECULAR CHARACTERIZATION; MESENCHYMAL TRANSITION;
D O I
10.1038/s41585-018-0020-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Metastatic disease is the principal cause of prostate-cancer-related mortality. Our ability to accurately recapitulate the spread of prostate cancer to bone - the most common site of metastasis - is critical to the development of novel metastasis-directed therapies. Several translational models of prostate cancer bone metastasis have been developed, including animal models, cell line injection models, 3D in vitro models, bone implant models, and patient-derived xenograft models. The use of these models has led to numerous advances in elucidating the molecular mechanisms of metastasis and innovations in targeted therapy. Despite this progress, current models are limited by a failure to holistically reproduce each individual element of the metastatic cascade in prostate cancer bone metastasis. In addition, factors such as accurate recapitulation of immunobiological events and improvements in tumour heterogeneity require further consideration. Knowledge gained from historical and currently used models will improve the development of next-generation models. An introspective appraisal of current preclinical models demonstrating bone metastases is warranted to narrow research focus, improve future translational modelling, and expedite the delivery of urgently needed metastasis-directed treatments.
引用
收藏
页码:403 / 421
页数:19
相关论文
共 232 条
  • [1] Ablin RJ., 2007, METASTASIS PROSTATE
  • [2] Alanee S, 2015, ANTICANCER RES, V35, P4145
  • [3] A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
    Anderson, DM
    Maraskovsky, E
    Billingsley, WL
    Dougall, WC
    Tometsko, ME
    Roux, ER
    Teepe, MC
    DuBose, RF
    Cosman, D
    Galibert, L
    [J]. NATURE, 1997, 390 (6656) : 175 - 179
  • [4] Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice
    Angelucci, A
    Gravina, GL
    Rucci, N
    Millimaggi, D
    Festuccia, C
    Muzi, P
    Teti, A
    Vicentini, C
    Bologna, M
    [J]. ENDOCRINE-RELATED CANCER, 2006, 13 (01) : 197 - 210
  • [5] A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer
    Antonarakis, Emmanuel S.
    Heath, Elisabeth I.
    Posadas, Edwin M.
    Yu, Evan Y.
    Harrison, Michael R.
    Bruce, Justine Y.
    Cho, Steve Y.
    Wilding, Gregory E.
    Fetterly, Gerald J.
    Hangauer, David G.
    Kwan, Min-Fun R.
    Dyster, Lyn M.
    Carducci, Michael A.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (04) : 883 - 892
  • [6] Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
    Araujo, John C.
    Trudel, Geralyn C.
    Saad, Fred
    Armstrong, Andrew J.
    Yu, Evan Y.
    Bellmunt, Joaquim
    Wilding, George
    McCaffrey, John
    Serrano, Sergio V.
    Matveev, Vsevolod B.
    Efstathiou, Eleni
    Oudard, Stephane
    Morris, Michael J.
    Sizer, Bruce
    Goebell, Peter J.
    Heidenreich, Axel
    de Bono, Johann S.
    Begbie, Stephen
    Hong, Jun H.
    Richardet, Eduardo
    Gallardo, Enrique
    Paliwal, Prashni
    Durham, Susan
    Cheng, Shinta
    Logothetis, Christopher J.
    [J]. LANCET ONCOLOGY, 2013, 14 (13) : 1307 - 1316
  • [7] ARGUELLO F, 1990, CANCER-AM CANCER SOC, V65, P98, DOI 10.1002/1097-0142(19900101)65:1<98::AID-CNCR2820650121>3.0.CO
  • [8] 2-K
  • [9] The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53
    Bajgelman, Marcio C.
    Strauss, Bryan E.
    [J]. PROSTATE, 2006, 66 (13) : 1455 - 1462
  • [10] PROGRESSION TO ANDROGEN INSENSITIVITY IN A NOVEL IN-VITRO MOUSE MODEL FOR PROSTATE-CANCER
    BALEY, PA
    YOSHIDA, K
    QIAN, W
    SEHGAL, I
    THOMPSON, TC
    [J]. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1995, 52 (05) : 403 - 413